Novo plans oral semaglutide trials, invests $2B in facilities

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) plans to start seven Phase IIIa trials of oral semaglutide ( NN9924) to treat Type II diabetes. The global PIONEER program will include six safety and efficacy trials and one cardiovascular trial of the long-acting glucagon-like peptide-1 (GLP-1) analog. Novo expects the first study to begin in 1Q16. ...